Document 2856
 DOCN  M94A2856
 TI    Triple combination therapy of Foscarnet.
 DT    9412
 AU    Convey P; Scolaro M; Brucker R
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):209 (abstract no. PB0267). Unique
       Identifier : AIDSLINE ICA10/94369719
 AB    OBJECTIVE: To evaluate the efficacy of Foscarnet, a non-nucleoside HIV-1
       reverse transcriptase inhibitor, given in combination with 2 nucleoside
       HIV reverse transcriptase inhibitors on immunological and virological
       markers. METHOD. Foscarnet was given intravenously (90 mg/kg every 12
       hours as an induction for 30 days, followed by a maintenance dose of 90
       mg/kg every 24 hours for 40-70 days), in combination with the nucleoside
       HIV-1 reverse transcriptase inhibitors zidovudine (300-600 mg/daily),
       and either dideoxyinosine (400-600 mg/daily based on kilogram weight) or
       dideoxycytidine (0.75-2.25 mg/daily) to 18 HIV-1 positive male patients
       with mean CD4 cell count (45 +/- 20), who had been given nucleoside
       HIV-1 inhibitors for 8-16 weeks prior to combination therapy. RESULTS:
       Patients with p24 antigenemia (14/18) showed a transient decline (30% to
       85%) in serum p24 concentration after the start of combination therapy
       with a gradual return to baseline levels before the end of the therapy
       regimen. Significant changes in CD4, CD8, B, NK cell, and B-2
       microglobulin levels were not observed during the course or after
       combination therapy. Hematologic and renal toxicities were observed.
       These were transient and resolved by dosage adjustment. CONCLUSION:
       Foscarnet in combination with AZT and DDI or DDC resulted in
       significant, though transient, reduction of p24 antigenemia.
 DE    Bone Marrow Diseases/CHEMICALLY INDUCED  Comparative Study
       Foscarnet/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/*THERAPEUTIC  USE
       Human  HIV Core Protein p24/BLOOD  HIV-1/*DRUG EFFECTS  Kidney
       Diseases/CHEMICALLY INDUCED  Reverse Transcriptase/*ANTAGONISTS & INHIB
       Treatment Outcome  Viremia/DRUG THERAPY  Zalcitabine/ADMINISTRATION &
       DOSAGE/ADVERSE EFFECTS/*THERAPEUTIC  USE  Zidovudine/ADMINISTRATION &
       DOSAGE/ADVERSE EFFECTS/*THERAPEUTIC  USE  CLINICAL TRIAL  MEETING
       ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).